Key Summary Points {#FPar1}
==================

Hereditary transthyretin amyloidosis (ATTRv) with polyneuropathy (ATTR-PN) is a rare genetic disorder.Survival in patients with ATTR-PN is largely characterized by and dependent on associated cardiac damage, but the impact of non-cardiac characteristics on survival are less defined.This study sought to assess the impact of non-cardiac baseline characteristics on survival in ATTR-PN.Survival in patients with ATTR-PN was highly variable and affected by non-Val30Met mutation and non-cardiac baseline characteristics, such as autonomic dysfunction, large fiber involvement, and late-onset disease.

Introduction {#Sec1}
============

Hereditary (variant) transthyretin amyloidosis (ATTRv) is a rare autosomal dominant disease whereby mutations in the transthyretin (TTR) gene destabilize the protein's native homeotetrameric structure and cause it to disassociate into amyloidogenic TTR monomers. As a result, insoluble amyloid fibrils accumulate in the peripheral and autonomic nerves, heart, gastrointestinal tract, kidneys, eyes, and connective tissues \[[@CR1], [@CR2]\]. Three phenotypes predominate in ATTRv amyloidosis: one is almost exclusively characterized by restrictive cardiomyopathy, another predominantly by polyneuropathy (ATTR-PN), and the third is a mixed phenotype \[[@CR3]--[@CR5]\].

ATTR-PN prevalence has been estimated at approximately 10,000 to 40,000 persons globally, with endemic foci in Portugal, Sweden, and Japan \[[@CR6], [@CR7]\]. Notably, disease phenotypes and penetrance across these endemic areas and elsewhere are often different, even for the same genotype \[[@CR8]\]. For example, inaugural symptoms of early-onset disease (\< 50 years old) include spontaneous burning or sharp pain, non-painful sensations (paresthesia and restless leg syndrome), and/or autonomic symptoms (sexual dysfunction, impaired bladder function, constipation alternating with diarrhea, early satiety, orthostatic dizziness and syncope) associated with damaged distal small myelinated and unmyelinated nerve fibers \[[@CR1]\]. Conversely, in late-onset disease, the combination of well-preserved unmyelinated nerve fibers and axonal sprouting is associated with impaired superficial and deep sensation, severe neuropathic pain, early distal motor involvement, but relatively mild autonomic symptoms at initial presentation \[[@CR1], [@CR9], [@CR10]\]. Absent early intervention with liver transplantation (LTx) or disease-modifying pharmacological treatments, ATTR-PN symptoms generally follow an ascending, proximally-oriented pattern as patients experience progressive debilitating polyneuropathy and inexorable loss of motor and organ functions.

Among persons with the classic disease phenotype, death has been reported to occur within 10--15 years of symptom onset, often from cachexia and malnutrition due to gastrointestinal complications \[[@CR11], [@CR12]\]. Prognostic survival factors include cardiac dysautonomia \[[@CR3]\] and the presence of a mutation other than the more common Val30Met (also referred to as p.Val50Me) tgenotype \[[@CR11], [@CR13]\]; both of which are associated with poorer survival.

Owing partly to its phenotypic heterogeneity but also to its rarity, our understanding of survival in ATTR-PN is limited and largely based on observations of persons with the Val30Met genotype. Furthermore, the progression of associated cardiac symptoms and their effects on survival have been the predominant focus in larger studies \[[@CR14]\]. However, as our understanding has evolved to reflect a heterogeneous disease, so too should our understanding of how this heterogeneity affects survival. This systematic review and analysis were conducted to describe the impact of non-cardiac clinicopathologic factors on survival and to assess survival trends among ATTR-PN subgroups.

Methods {#Sec2}
=======

The relevant evidence was assessed in a two-step process consisting of a systematic literature review to identify relevant data and a descriptive synthesis of those data. The target disease population was limited to persons with ATTR-PN.

Record identification and selection {#Sec3}
-----------------------------------

Records were identified via a systematic literature review per a pre-specified protocol and conducted according to modified American Academy of Neurology guidelines (AAN) \[[@CR6], [@CR15]\]. Structured electronic searches of PubMed/Medline and Scopus were conducted on 15 February 2019 to identify relevant primary studies without regard to language of origin or year of publication (See Electronic Supplementary Material Appendix A). Non-human studies and case reports (studies with \< 10 ATTR-PN patients) were excluded. Narrative reviews, systematic reviews, and meta-analyses were retained separately so that they could be searched for relevant primary reports not yielded by the electronic search.

The electronic search was supplemented with a hand search of conference materials from the International Symposium on Amyloidosis for the three most recent years held (2014, 2016, and 2018). The rationale for evaluating this supplemental material was twofold. First, the consideration of unpublished scientific materials is indicated by the AAN guidelines as a prerequisite for a comprehensive review \[[@CR15]\]. Second, materials presented at conferences may not have had time to be published while otherwise being relevant to the content of the present review. To avoid including duplicated information between published and conference sources, a conference record was included only when the information presented in the record was not also reported in an associated peer-reviewed manuscript authored by one or more of the same authors. If the same study was reported as a conference material and as a peer-reviewed manuscript, only the latter was considered for inclusion in this review.

Records yielded by the search strategy were de-duplicated and assessed for inclusion via three rounds of review (title, abstract, and full-text) based on a pre-specified rubric applied by two reviewers. Inconsistencies were adjudicated by consensus. Records were retained if they satisfied the following inclusion criteria:Human studies of adults (aged ≥ 18 years).Primary report.Reported survival among persons with ATTR-PN.Follow-up time for survival assessment was ≥ 5 years.Sample size is ≥ 10.Survival was assessed from a defined baseline event (symptom onset, diagnosis, or treatment initiation).Reported whether patients received disease-modifying pharmacologic treatment or LTx.Patients were symptomatic at the baseline event (assumed unless noted otherwise).

Records were also included in the descriptive analysis of clinicopathologic prognostic factors if they also included a multivariate assessment of the impact of clinicopathologic factors on survival.

Where sequential studies reported the same endpoints updated for the same cohort, the study with the longest follow-up time was retained, while those with shorter follow-up times were excluded---except where those with shorter follow-up times included relevant survival endpoints not reported in the more recent reports. Additionally, studies or outcomes for a given cohort were excluded if they included only patients with ATTRv variants associated with the phenotype predominantly characterized by cardiomyopathy (i.e., Val122Ile, Thr60Ala, Ser77Tyr, Ile84Ser, Val30Ala, and His90Asp). There was no a priori determination of which specific diagnostic methods or degree of documentation constituted a valid diagnosis of ATTR-PN. It was only required that the cohort in question was described as one comprised entirely of individuals with ATTR-PN.

Data Extraction and Synthesis {#Sec4}
-----------------------------

There were two survival outcome categories of interest for this study.

The first category included time-to-event survival outcomes, such as survival probabilities, survival percentages, failure probabilities, and failure percentages as measured from a baseline event (symptom onset, diagnosis, or treatment initiation). Where survival outcomes were reported in figures only, survival data were extracted using digitization software (Digitizeit, version 2.3; Braunschweig, Germany). Survival outcomes were pooled according to clinicopathologic characteristics reported in each study.

The impacts of clinicopathologic characteristics on survival were analyzed further. To mitigate the potentially biasing effects of uneven censoring and varying follow-up times among the extracted survival outcomes, patient-level survival data were reconstructed from reported aggregate-level outcomes using methods previously described \[[@CR16]-- [@CR18]\]. This dis-aggregation produced a register of patient-level survival observations, and those with "disease onset" as the baseline event (i.e., starting point from which survival was measured) were considered suitable for further analysis.

Modeling was used to derive survival curves from the aforementioned patient-level observations. Expecting latent heterogeneity within the dataset, we applied parametric mixture modeling that decomposed the overall survival curve into constituent curves. In other words, mixture models assume that the overall survival of a cohort is a function of two or more subgroups: each with its own survival curve that can be estimated with a standard parametric distribution. Specifically, the overall survival $\documentclass[12pt]{minimal}
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We stratified the survival data into three classes: (1) LTx versus no LTx; (2) early onset versus late onset; and (3) V30M (i.e, Val30Met) versus non-V30M genotype. Survival was estimated for each class via the method described above, and the mean survival in the class was calculated as the area under the curve. The mean \[95% confidence interval (CI)\] difference between classes was equal to the difference between survival means.

The second survival outcome category pertained to clinicopathologic prognostic survival factors. When assessed by univariate or multivariate analysis to determine their individual impacts on survival, these factors were recorded along with the directionality and magnitude of their effects and subsequently analyzed descriptively.

Retained studies were classified using the modified AAN guideline \[[@CR15]\] as has been reported previously \[[@CR6]\]. Evidence classifications ranged from class I (strongest evidence, low risk of bias) to class IV (weakest evidence, very high risk of bias). Risk of bias was evaluated primarily with respect to two considerations: the method by which the initial ATTR-PN diagnosis was made and the frequency of follow-up.

Compliance with Ethics Statement {#Sec5}
--------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec6}
=======

The electronic search of the peer-reviewed literature yielded 979 unique records, and the hand search of conference materials yielded 1014 records. In total, 1993 records were assessed in full, of which 35 were retained (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). These reported survival outcomes assessed over 265,346 person-years \[*N* = 11,116; median follow-up 10 (range 5--35) years\]. Most of the retained studies were of a longitudinal, observational design conducted between 1990 and 2007. Risk of bias was low, and evidentiary quality of the retained studies was moderate overall (Table [1](#Tab1){ref-type="table"}).Fig. 1Flowchart summarizing the process of study adjudicationTable 1Summary of the 35 studies retained for analysisFirst author of study, year of publication \[reference number\]*N* (size of cohort)CountryDiagnostic method(s)Baseline periodicity^a^Follow-up (years)^b^Evidence class, risk of bias^c^Adams, 2000 \[[@CR19]\]45Multiple^i^Tissue biopsy + genetic testing1993--199961, LowAdams, 2018 \[[@CR20]\]225MultipleNR2013--201671, LowAlgalarrondo, 2015/2016 \[[@CR3], [@CR21]\]^d^215FranceTissue biopsy + genetic testing1993--2011101, LowArruda-Olson, 2013 \[[@CR22]\]37USATissue biopsy1980--201062, LowBarrosso, 2017 \[[@CR23]\]75MixedTissue biopsy + genetic testingNR--2014101, LowBittencourt, 2002 \[[@CR24]\]24BrazilTissue biopsy + genetic testing^o^1993--199972, ModerateCarvalho, 2002 \[[@CR25]\]35PortugalGenetic testing1992--200052, ModerateCoelho, 2018 \[[@CR26]\]3160PortugalMixed1992--2016242, ModerateCoutinho, 2013 \[[@CR27]\]106^e^PortugalGenetic testing1998--2010131, ModerateCoutinho, 2017 \[[@CR27]\]232PortugalNR1998--2015151, ModerateEriczon, 2015 \[[@CR28]\]1623Multiple^j^NR1990--2010202, HighFranz, 2013 \[[@CR29]\]21GermanyGenetic testing1996--2011102, ModerateGonzalez-Lopez, 2018 \[[@CR30]\]118SpainNRNR253, HighInes, 2018 \[[@CR31]\]3160Portugal^k^NRNR--2016353, HighKawaji, 2014 \[[@CR32]\]27JapanTissue biopsy + genetic testing1987--201171, LowLagarto, 2016 \[[@CR33]\]116PortugalGenetic testing2006--201472, ModerateLoavenbruck, 2016 \[[@CR34]\]41^f^USATissue biopsy + genetic testing1993--2013201, LowLobato, 2004 \[[@CR35]\]62PortugalTissue biopsy + genetic testing^p^1989--200091, ModerateMariani, 2015 \[[@CR36]\]194France^l^Tissue biopsy + genetic testing1988--2010252, LowMunar-Ques, 2005 \[[@CR37]\]102SpainTissue biopsy ± genetic testing1976--200329^r^3, ModerateOhya, 2011 \[[@CR38]\]34JapanTissue biopsy ± genetic testing1994--2006103, ModerateOkamoto, 2011 \[[@CR39]\]104SwedenTissue biopsy ± genetic testing1990--2008251, LowOkamoto, 2009 \[[@CR40]\]141SwedenTissue biopsy ± genetic testing1990--2008201, LowOkumura, 2016 \[[@CR41]\]65JapanGenetic testing1990--2010202, ModeratePlante-Bordeneuve, 1998 \[[@CR42]\]65FranceGenetic testing ± tissue biopsy1988--1997102, HighSuhr, 2016 \[[@CR11]\]264Multiple^j^NR1991--2012102, HighSuhr, 2002 \[[@CR43]\]51^g^SwedenTissue biopsy + genetic testing1990--2000202, ModerateSwiecicki, 2015 \[[@CR44]\]110 ^h^USAFamily history ± genetic testing1970--201384, HighTakei, 2005 \[[@CR45]\]43JapanGenetic testing1993--2004102, ModerateTashima, 1998 \[[@CR46]\]120Multiple^m^Tissue biopsy + genetic testing^q^1973--1998243, ModerateWixner, 2015 \[[@CR47]\]115SwedenTissue biopsy + genetic testing1990--201191, LowYamamoto, 1998 \[[@CR48]\]116JapanTissue biopsy + family history1974--1995204, HighYamamoto, 2007 \[[@CR49]\]86Multiple^m^Tissue biopsy + genetic testing1990--2005161, LowYamashita, 2012 \[[@CR50]\]80Multiple^n^Tissue biopsy + genetic testing1990--2010202, LowYamashita, 2018 \[[@CR51]\]104JapanTissue biopsy ± genetic testing2000--2017102, Low*HTx* Heart transplantation, *KTx* kidney transplantation, *LTx* liver transplantation, *mBMI* modified body mass index, *NR* not reported^a^Refers to the time-period over which the study was conducted^b^Refers to maximum number of years from the baseline event at which survival outcomes were reported^c^Evidence grades range from 1 (best) to 4 (worst)^d^Note that two studies are reported here^e^Refers to the matched cohort of LTx (*n* = 53) ves. non-LTx (*n  *= 53)^f^Refers to the transthyretin amyloidosis cohort (*n* = 41) and excludes the primary amyloidosis cohort (*n* = 60)^g^Refers to the transthyretin amyloidosis cohort (*n * = 51) and excludes the control cohort (*n * = 19)^h^Refers to Val30Met (*n * = 42), Ser77Tyr (*n * = 15), and other mutations (*n  *= 53) and excludes Thr60Ala (*n  *= 68) and Val122Ile (*n *= 28)^i^France, Germany, and Portugal^j^Portugal, France, Sweden, USA, Brazil, Spain, Japan, UK, Germany, Italy, Australia, Switzerland, Netherlands, Belgium, Argentina, Canada, Denmark, China, and Singapore^k^The geographical origin of the patient cohort was not explicitly stated in the report. Portugal was assumed based on authors' affiliations^l^All patients were treated in France, but *n * = 110 (57%) were Portuguese^m^Sweden and Japan^n^Japan, Sweden, Australia, and USA^o^Refers to definitive testing performed after LTx^p^Genetic testing performed on first-degree relatives for *n * = 3 (5%) patients^q^Genetic testing was performed only on patients living past 1997^r^Not reported and so imputed as the year of publication (2005) minus the earliest baseline year (1976)

Survival was first assessed descriptively and by combining the aggregate-level data into groups according to distinguishing characteristics known to the authors to impact survival (i.e., genotype, whether one has received a liver transplant, and whether one has early- or late-onset disease). This preliminary assessment (figures not shown but available upon request) confirmed the need for mixture modeling, which was conducted using disaggregated data from the 12 studies (45 observations, *N* = 3348) with disease onset as the baseline timepoint.

Disaggregated survival data were analyzed with parametric mixture modeling to assess survival differences among patient groups defined by factors known to affect survival. The most pronounced survival difference (reported here and subsequently as mean years from symptom onset to death) was observed between LTx and non-LTx patients: 26.0 (95% CI 25.0--27.9) versus 12.0 (95% CI 11.2--13.0); difference 15.0 (95% CI 13.7--16.3) (Fig. [2](#Fig2){ref-type="fig"}). Also significant was the survival difference between early-onset versus late-onset patients: 24.7 (95% CI 23.4--26.0) versus 12.9 (95% CI 11.0--13.8); difference 11.8 (95% CI 10.1--13.4) (Fig. [3](#Fig3){ref-type="fig"}). Combining these factors demonstrated that LTx patients with early-onset disease had significantly longer survival than LTx patients with late-onset disease: 26.6 (95% CI 25.6--27.4) versus 13.1 (95% CI 11.6--14.7); difference 13.5 (95% CI 11.7--15.3) (Fig. [4](#Fig4){ref-type="fig"}). However, the same comparison among non-LTx patients yielded a non-significant difference (12.7 vs. 12.5).Fig. 2Comparison of modeled survival curves for patients who underwent liver transplantation (*LTx*) with those who did not (*No LTx*) demonstrates the survival benefit associated with LTxFig. 3Cohorts with disease that was not early onset (*Not Early onset*) experienced markedly shorter survival than did cohorts with early-onset disease (*Early onset*)Fig. 4Impact of timing of disease onset. Cohorts with LTx and no early-onset disease (*LTx + NO early onset*) are shown to have shorter modeled survival versus cohorts with LTx and early-onset disease (*LTx + Early onset*)

A comparison between V30M genotype versus non-V30M genotype indicated longer survival for V30M (22.2 vs. 10.4), but the trend was not significant owing to limited observations for non-V30M patients.

Of the 35 retained studies, eight reported the outcomes of multivariate survival analysis (Table [2](#Tab2){ref-type="table"}). Other than LTx status, the clinicopathologic survival factors identified as having a statistically significant impact on survival included sex/gender, pre-LTx disease duration, and symptoms of disease progression \[e.g., modified body mass index (mBMI), serum albumin levels at the time of LTx, and the presence/absence of urinary incontinence at the time of LTx\]. These observations indicated that female sex/gender, ≤ 7-year disease duration by the time of LTx, mBMI \> 600, and a lack of urinary incontinence at LTx were all associated with improved survival versus matched comparisons.Table 2Non-cardiac baseline prognostic survival factors and associated effects assessed by multivariate analysisDomain^a^DescriptionSurvival difference (years)Mitigating factor(s)Genotype Mariani, 2015 \[[@CR36]\]Val30Met vs. Non-Val30Met1 (8 vs. 7)Among No LTx Mariani, 2015 \[[@CR36]\]Val30Met vs. Non-Val30Met4 (17 vs. 13)Among LTxSex/gender Munar-Ques, 2005 \[[@CR37]\]Female vs. male− 1 (9 vs. 10)None reported Okamoto, 2009 \[[@CR40]\]Female vs. male≥ 4 (≥ 25 vs. 21)Among LTx Okamoto, 2009 \[[@CR40]\]Female vs. male≥ 4 (≥ 25 vs. 21)Among LTx with early onset Okamoto, 2009 \[[@CR40]\]Female vs. male≥ 9 (≥ 20 vs. 11)Among LTx with late onset Yamamoto, 1998 \[[@CR48]\]Female vs. male1 (11 vs. 10)Among no LTxPre-LTx disease duration Bittencourt, 2002 \[[@CR24]\]\< 7 years vs. ≥ 7 years≥ 6 (≥ 7 vs. 1)None reported Okamoto, 2009 \[[@CR40]\]\< 7 years vs. ≥ 7 years≥ 4 (≥ 25 vs. 21)None reported Suhr, 2002 \[[@CR43]\]\< 7 years vs. ≥ 7 years3 (14 vs. 11)Lower baseline mBMI in \< 7 years Yamamoto, 2007 \[[@CR49]\]\< 7 years vs. ≥ 7 years≥ 17 (≥ 20 vs. 3)None reportedBiometrics/symptoms Suhr, 2002 \[[@CR43]\]mBMI \> 600 vs. \< 600 (at LTx)3 (14 vs. 11)Pre-LTx disease duration was \< 7 vs. ≥ 7 years Yamamoto, 2007 \[[@CR49]\]mBMI \> 600 vs. \< 600 (at LTx)≥ 17 (≥ 20 vs. 3)Pre-LTx disease duration was \< 7 vs. ≥ 7 years Bittencourt, 2002 \[[@CR24]\]Serum albumin (at LTx)≥ 6 (≥ 7 vs. 1)Among LTx Adams, 2000 \[[@CR19]\]Urinary incontinence (at LTx)≥ 4 (≥ 5 vs. 1)Among LTx*mBMI* Modified body mass index^a^Presented as first author of study, year of publication \[reference number\]

Discussion {#Sec7}
==========

This synthesis of published evidence illustrates the heterogenous nature of survival among persons with ATTR-PN and highlights a number of patient subgroups for whom survival differs from the commonly-cited 10--15 years---in some cases markedly less \[[@CR52]\]. For non-LTx patients, heterogeneity was most evident among those with non-Val30Met genotypes for whom median survival was poorer compared to persons with the ATTRv Val30Met (6.3 vs. 12.1 years after onset). Furthermore, those who underwent LTx had better survival than those who were untreated (21.8 vs. 9.6 years). Evidence of the impact of disease-modifying pharmacological treatments was limited but demonstrated survival benefits of tafamidis versus no treatment and potentially versus LTx.

Aside from genotype and treatment experience, other baseline non-cardiac clinicopathologic characteristics associated with shorter survival included longer disease duration before LTx, late-onset disease, and lower mBMI. Given the previously known associations of many of the non-cardiac clinicopathologic survival factors identified in this study with baseline disease progression and the negative relationship between baseline disease progression and survival time \[[@CR53]\], some of our findings are unsurprising. There were, however, notable studies demonstrating the impact of competing prognostic factors on survival. For example, at 20 years of follow-up after ATTRv Val30Met onset, Okamoto et al. \[[@CR40]\] reported a non-significant effect of sex on survival at 15 years of follow-up after disease onset for those with early-onset disease (76 vs. 78%, *p* = 0.33); in contrast, when the same comparison was evaluated among LTx patients with late-onset disease, the difference was significant \[69% (females) vs. 37% (males); *p* = 0.02\]. The significant effect of sex in late-onset patients---who typically present with more advanced cardiac symptoms---despite no such finding in early-onset patients highlights intra-genotype survival differences that may be mitigated by sex and disease onset. Another example was reported by Adams et al. \[[@CR19]\] who demonstrated that the survival benefits of LTx can be entirely negated by advanced disease progression at baseline, as indicated by a Norris score ≤ 55.

We also assessed the risk of bias and evidentiary quality of the records retained in this review and, notably, both were within acceptable limits overall. These metrics were largely based on the definitiveness of the ATTRv amyloidosis diagnosis (i.e., genetic and histological testing) and the transparency by which diagnoses were reported. Given that many of the retained records reported LTx cohorts and that histological and genetic testing are often required for LTx \[[@CR25], [@CR53]\], it follows that the records retained for this review would be scored highly.

This study has limitations which should be noted. First, in 1996 there began a more concerted, evidence-driven effort to optimize patient selection for LTx globally \[[@CR40], [@CR53]\]. LTx-associated survival benefits reported here may have been downwardly biased due to our having grouped data from patients who underwent LTx in pre- and post-1996 time periods, whereas survival after LTx in a contemporary treatment setting may be longer. This implies a related limitation: that due to lack of evidence it was not possible to control for patients having been at different stages of disease progression at the time of LTx or starting other treatments. Third, this study is limited to patients who received no treatment, underwent LTx, or received tafamidis due to these being the only ATTR-PN patients with long-term survival outcomes (i.e., ≥ 5 years). There are other treatments available or currently being evaluated to treat ATTR-PN, but there are as yet insufficient survival follow-up data on these treatments. Lastly, survival is only one outcome---albeit a critical one---for evaluating ATTR-PN disease progression, whereas progression of neuropathy would also have been an informative endpoint had sufficient evidence been available. Similarly, our survival analysis did not consider the implications of cardiac sequelae, which have been reported extensively in the literature and are important because our objective was to look at the impact of non-cardiac factors.

Conclusion {#Sec8}
==========

Notwithstanding the aforementioned limitations, this study evaluates survival in individual ATTR-PN subgroups for whom survival has often been imprecisely defined. Our estimates indicate that 10- to 15-year survival is an overly-optimistic assumption for many patients. Median survival for untreated patients with non-Val30Met genotypes is considerably worse than that for Val30Met disease, with survival approximately 6 years from symptom onset in the former and approximately 12 years in the latter. Conversely, the 10- to 15-year survival estimate that is commonly used may underestimate the benefits of definitive treatment with LTx or disease-modifying treatment with medications. Median survival may range from 14 to 25 years from symptom onset in treated patients, depending on the genotype of the disease and the extent of disease progression by the time treatment is started. Nevertheless, the evidence presented here demonstrates that ATTR-PN is quite heterogenous and, consequently, that our understanding of the prognosis of these patients should be similarly nuanced.

Electronic supplementary material
=================================

 {#Sec9}

Below is the link to the electronic supplementary material.Supplementary material 1 (DOCX 14 kb)

**Enhanced digital features**

To view enhanced digital features for this article go to 10.6084/m9.figshare.11891175.

Funding {#FPar2}
=======

This study, including the rapid service publication fee, was funded by Pfizer, Inc.

Authorship {#FPar3}
==========

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures {#FPar4}
===========

Leslie Amass and Michelle Stewart are employees of Pfizer Inc. and hold stock and/or stock options. Marc F Botteman and John A Carter are employees of Pharmerit International, which was funded by Pfizer Inc. for study design, execution, analysis, and manuscript development. Alejandra González‐Duarte previously received support from Alnylam Pharmaceuticals and Pfizer Inc. for her role as a principal investigator of studies sponsored by these entities. Isabel Conceição previously received support as principal investigator from Alnylam Pharmaceuticals, IONIS Pharmaceuticals, and Pfizer Inc. Alejandra González‐Duarte and Isabel Conceição serve on the THAOS advisory board, which is sponsored by Pfizer Inc.

Compliance with Ethics Guidelines {#FPar5}
=================================

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability {#FPar6}
=================

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access {#d29e2212}
===========

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article\'s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\'s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.
